News

INNOVEIT Weeks - EIT Event series in Autumn 2022

Published on | 3 years ago

Programmes EIC EIT Horizon Europe Digital Europe

The European Institute of Innovation and Technology (EIT) is organising its flagship initiative ‘INNOVEIT’ in Autumn 2022. It is a series of events taking place between September and October 2022 in 12 different locations across Europe.

What INNOVEIT offers to its participants:

  • Find out how you can join the EIT Community – no matter what stage of the innovation journey you’re on
  • Meet representatives of industry, universities, start ups and unicorns, top researchers and scientists as well as investors involved in EIT activities
  • See the most inspiring innovations from the EIT Community compete for the prestigious EIT Awards


The different events of the INNOVEIT weeks can be found in our event calendar or on the EIT programme page on our website (bottom of the page). You can also directly visit the EIT's INNOVEIT website - more information about the different events and the event locations coming soon on this website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1786 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.